Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Psoriasis: Update Bulletin #2 [January 2019]

Product Code:
596201035
Publication Date:
January 2019
Format:
PDF
Price:
£1,140

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from the US and EU on a variety of recent events in the psoriasis market. Topics covered include opinions regarding Janssen’s announcement of the Phase III ECLIPSE study demonstrating that Tremfya (guselkumab) was superior to Cosentyx (secukinumab; Novartis) in treating adults with moderate to severe plaque psoriasis; insights on how biosimilar adalimumab is expected to impact the European and US psoriasis market; as well as Menlo Therapeutics’ announcement of positive top-line results from the Phase II PSORIXA clinical trial of serlopitant, an oral neurokinin 1 receptor antagonist for pruritus associate with plaque psoriasis.

Business Questions:

• How do KOLs view the Phase III ECLIPSE data for Tremfya (guselkumab)?
• Do KOLs have any concerns regarding Tremfya?
• How do KOLs envisage future prescribing of anti-IL17s and anti-IL23s?
• What impact is biosimilar adalimumab expected to have on the European and US psoriasis market?
• What are KOLs’ opinions regarding serlopitant and how could it potentially be used if approved?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved